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Mass spectrometryIn the present work we show that murine ATXN3 (ATXN3Q6) nuclear uptake is promoted by
phosphorylation on serine 29, a highly conserved residue inside the Josephin domain. Both casein kinase
2 (CK2) and glycogen synthase kinase 3 (GSK3) are able to carry out phosphorylation on this residue. S29
phosphorylation was initially assessed in vitro on puriﬁed ATXN3Q6, and subsequently conﬁrmed in
transfected COS-7 cells, by MS analysis. Site-directed mutagenesis of S29 to an alanine was shown to strongly
reduce nuclear uptake, in COS-7 transiently transfected cells overexpressing ATXN3Q6, while substitution
with phospho-mimic aspartic acid restored the wild-type phenotype. Finally, treatment with CK2 and GSK3
inhibitors prevented S29 phosphorylation and strongly inhibited nuclear uptake, showing that both kinases
are involved in ATXN3Q6 subcellular sorting. Although other authors have previously addressed this issue,
we show for the ﬁrst time that ATXN3 is phosphorylated inside the Josephin domain and that S29
phosphorylation is involved in nuclear uptake of ATXN3.+39 0264483409.
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Ataxin-3 (ATXN3), the protein involved in SCA3 (Spinocerebellar
Ataxia type 3), is a ubiquitously expressed protein [1–3], possessing a
conserved N-terminal region, the Josephin domain, and a less
conserved, unstructured C-terminus containing the poly-Q stretch
[4–6]. The structure of the Josephin domain has been determined by
NMR [7,8].
Many hypothesis have been formulated as regards ATXN3 function
[9–13]. On the whole, recent data suggest a role for ATXN3 in
proteasome mediated protein degradation, as a deubiquitinating
enzyme which regulates ﬂow through the ERAD (ER Associated
Degradation) [7,14].
ATXN3 is mostly cytosolic, although it also localizes in the nucleus
[15,16]. Nuclear localization is particularly relevant to SCA3 patho-
genesis, in that pathologically expanded ATXN3 gives rise to nuclear
aggregates. Different authors [13,17–20] presented evidence suggest-
ing a model of the disease in which the full-length pathological
protein is recruited into aggregates by “toxic” poly-Q containing
fragments. In our laboratory we observed that puriﬁed ATXN3
underwent slow autolytic fragmentation [21] and subsequently
showed that pathological ATXN3was less proteolyzed than its normal
counterpart [22]. Besides, some authors showed that ATXN3 is the
target of caspase 1 [13], while others demonstrated that ATXN3 is
cleaved by calpains [20,23].The role of phosphorylation in SCA3 pathogenesis has not yet been
thoroughly investigated. Tait and coworkers have shown the
presence, in ATXN3 primary structure, of two putative casein kinase
(CK2) phosphorylation sites [15]. Other authors [24] have shown that
ATXN3 interacts with CK2. More recently Mueller and coworkers [25]
showed that ATXN3 phosphorylation by CK2 on S340 and S352
promotes ATXN3 nuclear uptake. Protein kinase CK2 is a highly
conserved, ubiquitously expressed Ser/Thr kinase, extremely abun-
dant in the brain. This pleiotropic enzyme is involved in the control of
various cellular processes [26], amongst which neural development
[27]. Moreover, the catalytic α-subunit of CK2 is an inhibitor of the
neuronal kinase Cdk5 [28]. Fei and coworkers [29] showed that
ATXN3 is also phosphorylated by glycogen synthase kinase 3β (GSK
3β), a Ser/Thr kinase, particularly abundant in the central nervous
system [30] that plays a key role in a number of cellular processes [31].
In this work we ﬁnd that a murine form (ATXN3Q6) [32,33], is
phosphorylated by CK2 and GSK3 on serine 29, a highly conserved
residue inside the Josephin domain. We also show that phosphory-
lation at this residue controls nuclear uptake of ATXN3, a key event in
SCA3 pathogenesis.
2. Materials and Methods
2.1. Constructs
cDNA coding for murine ATXN3Q6, previously subcloned in our
laboratory into plasmid pGEX-6P-1, was cut with BamHI and XhoI
restriction enzymes and subcloned into plasmid pcDNA3X(+)HA
(Invitrogen UK Ltd. Paisley, England). Subsequently, ATXN3 coding
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PCR from pcDNA3X(+)HA and subcloned into plasmid pcDNA3.1/myc-
His, digested with the same enzymes, in frame with a c-myc epitope;
the STOP codon was eliminated by site-directed mutagenesis.
S29A and S29D mutants were obtained by PCR using Quik-Change
Site directed Mutagenesis Kit (Stratagene La Jolla, CA USA), according
to the manifacturer's instructions. The correct insertion of cDNAs in
expression vectors and the presence of themutations were veriﬁed by
automated sequencing using vector oligonucleotide primers (T7 and
BGH).
All constructs in pcDNA3.1/myc-His, carrying N-terminal HA and C-
terminal c-myc epitopes, were hosted and ampliﬁed in E. coli strain
DH5α, while protein expression was achieved after transient
transfection of COS-7 cells or SHSY-5Y cells. Cultures were carried
out in 94 mm plates in DMEM containing 10% fetal bovine serum
(FBS), 100 U/ml penicillin, 100 μg/ml streptomycin and 4 mM
glutamine (COS-7 cells) or in F12 and DMEM containing 10% fetal
bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin and
4 mM glutamine (SHSY-5Y cells). Cells were subsequently transiently
transfected with FuGENE6 (Roche Diagnostics Mannheim, Germany),
according to themanufacturer's instructions. To inhibit CK2 and GSK3,
COS-7 cells were incubated for 24 hours at 37 °C with either 5 or
10 µM CK2 inhibitor (TBB, Sigma St. Louis, Mo, USA) and/or with
10 µMGSK3 inhibitor (SB216763, Sigma St. Louis, Mo, USA). 24 h after
transfection, cells were harvested and tested for subcellular localiza-
tion of exogenous ATXN3 by blotting and detection with c-myc
antibody. Cell viability was assessed through MTT test (Sigma St.
Louis, Mo, USA), performed according to the manufacturer's
instructions.
2.2. Cell fractionation
24 h after transfection, COS-7 cells (6×105 cells/plate, cultured in
94 mm plates) or SHSY-5Y cells (1×106 cells/plate, cultured in
94 mm plates) were harvested and resuspended in 10 mM (Na)PO4,
100 mM NaCl, pH 7.4, 0.5% NP-40, supplemented with protease
inhibitors (Roche Diagnostics Mannheim, Germany). After incubating
40 min on ice, nuclei were pelleted by centrifugation at 4000×g for
15 min at 4 °C. The supernatant, was centrifuged at 15,000×g for
30 min at 4 °C, yielding the cytosolic fraction. Nuclei were resus-
pended in 50 mMHEPES pH 7.9, 0.75 mMMgCl2, 0.5 mM EDTA, 0.5 M
NaCl, 12.5% glycerol, 5 mM DTT and protease inhibitors. After
incubating 1 h on ice nuclei were centrifuged at 15,000×g for
30 min at 4 °C: the supernatant represented the nuclear fraction.
2.3. Immunoprecipitation
1000 μg total protein extract, obtained from ATXN3Q6 over-
expressing COS-7 cells, was incubated overnight at 4 °C with an
anti-ATXN-3 polyclonal antibody, (2 μg of Z46 antibody (Primm
Cambridge, MA USA). The total extract was subsequently incubated
with Protein A-Sepharose ™-CL-4B (Amersham GE Healthcare,
Uppsala, Sweden) for 2 h at 4 °C. After incubation the resin was
washed 3 times with NP40 buffer (50 mM Tris pH 7.5, 150 mM NaCl,
15 mMMgCl2 and 1% NP40) and ataxin-3 was eluted by boiling in SDS
buffer.
2.4. SDS-PAGE and western-blot analysis
SDS-PAGE and Western-blot were carried out by standard
procedures. PVDF Immobilon™ P (Millipore Billerica, MA USA)
membranes were blocked for 1 h in PBS , containing either 5% (w/
v) dried milk (for anti-c-myc antibody) or in 5% (w/v) bovine serum
albumin (BSA) (Sigma St. Louis, Mo, USA) (for anti-ﬁbrillarin and anti-
Phosphoglycerate kinase (PGK) antibodies). Membranes were subse-
quently probed overnight in PBS 1% dried milk, with anti-c-mycmouse monoclonal antibody (1:1000) (Santa Cruz Biotechnology Inc.
Santa Cruz, CA. USA). Control incubations with anti-ﬁbrillarin
(1:5000) (Encor Biotechnology Gainesville, FL, USA) and with 22C5
anti-PGK (1:1000) (Molecular Probes, Invitrogen UK Ltd. Paisley,
England) mouse monoclonal antibodies were also carried out
overnight in PBS, containing 1% (w/v) BSA, 0.1% (v/v) Tween20 and
1% (w/v) BSA respectively. Membranes, probed with mouse anti-
bodies, were incubated for 1 h with an anti-mouse horseradish
peroxidase-conjugated IgG (1:3000) (Calbiochem Darmstadt,
Germany) in PBS, containing 0.1% (v/v) Tween20 and 1% (w/v)
dried milk. Detection of antibody binding was carried out with ECL
(Amersham GE Healthcare, Uppsala, Sweden), according to the
manufacturer's instructions.
Protein levels were quantiﬁed by densitometry of scanned not
saturated X-ray ﬁlms using the NIH Image-based software Scion
Image (Scion Corporation). Quantiﬁcation data are a mean of three
independent experiments; bands intensities were normalized on
ﬁbrillarin and PGK controls. Statistical analysis was performed using t-
Student test, results signiﬁcance was indicated with pb0.05.
2.5. Acid silver stain
SDS-PAGE was ﬁxed for 1 h in 40% Ethanol, 10% acid acetic and for
2 days in 5% ethanol, 5% acid acetic; the gel was subsequently washed
3 times for 20 min in 30% ethanol and incubated for 1 min in 0.8 mM
sodium tiosulfate. The gel was then incubated in 11.8 mM silver
nitrate, 0.02% formaldehyde for 20 min and subsequently washed
twice with water for 20 sec and developed with 556 mM sodium
carbonate, 0.02% formaldehyde, 0.02 mM sodium tiosulfate. Develop-
ing was stopped with 50% ethanol, 12% acid acetic; the gel was
washed with water for 10 min and conserved at 4 °C in 1% acid acetic.
2.6. Immunoﬂuorescence and confocal analysis
COS-7 cells were plated onto coverslips (2.5×104 cells/coverslip)
and grown for 24 h before transfection. Cells were transfected
overnight with FuGENE6 (Roche Diagnostics Mannheim, Germany);
24 h after transfection, cells were ﬁxed for 20 min in 3% (w/v)
paraformaldehyde in PBS and quenched for 30 min with 50 mM
NH4Cl in PBS. Permeabilization was carried out by incubating the cells
in the presence of 0.3% (w/v) saponin in PBS (7 min for 3 times). Cells
were then doubly stained with anti-c-myc mouse monoclonal
antibody (Santa Cruz Cruz Biotechnology Inc. Santa Cruz, CA USA)
and anti-HA rabbit polyclonal antibody (Sigma St. Louis, Mo USA).
After extensive washes, cells were incubated with donkey anti-mouse
Cy3 conjugated antibody and donkey anti-rabbit Cy2 conjugated
antibody. All antibodies were from Jackson ImmunoResearch Labora-
tories (West Grove, PA USA). Incubations andwasheswere carried out
at room temperature in PBS, 0.3% (w/v) saponin. Cells were ﬁnally
incubated for 15 min with the nuclear marker TO-PRO-3 iodide
(Molecular Probes, Invitrogen UK Ltd Paisley, England). Confocal
microscopy was performed using a Leica Mod. TCS-SP2 (Leica
Microsystem). Image processing was performed with Leica Confocal
Software (LCS) and Adobe Photoshop Software. Confocal microscopy
images were collected under the same conditions in order to compare
ﬂuorescence intensities among different images. About 120 cells were
examined in each image and 6 images were analyzed for each
experiment; the nuclear region was circumscribed and its mean
ﬂuorescence intensity was evaluated. Statistical analysis was per-
formed using t-Student test, results signiﬁcance was indicated with
pb0.05.
2.7. Puriﬁcation from E.coli
ATXN3Q6-encoding cDNA, cloned into plasmid pGEX-6P-1, was
used to transform E. coli strain BL21 codon plus RIL, to express ATXN3
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medium and induced at A600 0.8, for 3 h with 50 µM IPTG. In order to
obtain crude extracts, cells were resuspended in lysis buffer (10 mM
potassium phosphate, pH 7.2, 150 mM NaCl, 1 mM phenylmethane-
sulfonyl ﬂuoride, 5 mM DTT, 100 mMMgCl2) plus 1 mg/ml lysozyme
and incubated for 1 h at 4 °C. Cell suspensionwas then frozen at -80 °C
for 20 min and thawed; DNase I (0.15 mg/g of cells, wet weight) and
1% Triton X-100 were added, and the sample further incubated for
30 min at room temperature. After centrifugation for 30 min at
18,000×g, the supernatant was incubated with Glutathione Sephar-
ose 4B resin (1 ml/g of cells, wet weight) (GE Healthcare, Uppsala,
Sweden) for 40 min at 4 °C; the sample was subsequently loaded onto
the column. After washing with 10 volumes of PBS (10 mM potassium
phosphate, pH 7.2, 150 mM NaCl) and equilibration with 10 volumes
of cold Cleavage Buffer (50 mM Tris-HCl, pH 7.0, 150 mM NaCl, 1 mM
EDTA, 1 mM DTT), ATXN3 was cleaved from fusion partner by
overnight incubation at 4 °C with Prescission Protease (80 U/ml
resin) (GE Healthcare, Uppsala, Sweden)). Puriﬁed ATXN3 was eluted
with 10 ml of Cleavage buffer. Protein concentration was assayed
through Coomassie brilliant blue G-250 from Pierce (Pierce Biotech-
nology, Rockford, IL), using bovine plasma immunoglobulin as a
standard protein.2.8. In vitro phosphorylation by CK2
ATXN3Q6 puriﬁed from E. coli was dialyzed for 3 h at 4 °C against
50 mM Tris pH 8, 150 mM NaCl, 10 mM MgCl2, with a 14 kD cut-off
membrane. ATXN3Q6 (40 µg) was then incubated for 30 min at 30 °C,
under shaking, with 1 µg (200 U) CK2 (BIOMOL international
Plymouth Meeting, PA USA) in the presence of 1 mM ATP. The sample
was then subjected to MALDI-TOF analysis. If needed, phosphoryla-
tion was checked using [γ-32P]ATP, as previously reported [34].2.9. In vitro phosphorylation by GSK3
ATXN3Q6 puriﬁed from E. coli was dialyzed for 3 h at 4 °C in GSK3
buffer (25 mM MOPS pH 7.2, 12.5 mM β-glycerophosphate, 5 mM
EGTA, 2 mM EDTA, 25 mMMgCl2, 0.25 mMDTT, 50 ng/ µl BSA) with a
14 kD cut-off membrane. ATXN3Q6 (40 µg) was then incubated with
1 µg (100U) GSK3 (BIOMOL international PlymouthMeeting, PA. USA)
and ATP 100 µMat 30 °C for 30 min. The sample was then subjected to
analysis.2.10. Mass spectrometry analysis
ATXN3Q6, phosphorylated in vitro by either CK2 or GSK3 as
described above, was subjected to reduction and alkylation in solution
by iodoacetamide and incubated with GluC endoproteinases (1:25
enzyme/protein, w/w) overnight at 37 °C. Following acidiﬁcation, the
peptide mixture was loaded onto a MALDI plate using ZipTip C18
(Millipore, Bedfor, MA-USA) with a matrix of α-ciano-4-hydroxy-
cinnamic acid. The same procedure was applied for the analysis of
ATXN3Q6 in transfected cells. In the latter case the protein, separated
by SDS-PAGE, was subjected to in situ digestion with Glu-C
endoproteinase (1:10 enzyme/protein, w/w) and peptide extraction
with 40% CH3CN in 0.1% TFA before loading onto the MALDI plate.
Mass spectrometry analysis was carried out on a Bruker Daltonics
Reﬂex IV instrument (Bruker Daltonics, Milano, Italy) equippedwith a
nitrogen laser, operating in positive and negative linear mode. Each
spectrum was accumulated for at least 200 laser shots and Bruker
peptide calibration standards were used for calibration.
MS/MS analysis was carried out on a MALDI TOF/TOF Autoﬂex III
(Bruker Daltonics, Milano, Italy). Data were acquired and processed
using Biotools software (Bruker Daltonics, Milano, Italy).3. Results
3.1. ATXN3 is phosphorylated in vitro by Casein Kinase II
A bioinformatic analysis, performed through NetPhos 2.0, Net-
PhosK 1.0 and ScanProsite servers available at www.expasy.ch, as well
as Phosidia server available at Phosidia.com, showed the presence,
along ATXN3 aminoacidic sequence, of a series of phosphorylation
consensus sites for several kinases. However, within the Josephin
domain, the only structured part of the protein, only one residue (S29)
was predicted by all four servers to be phosphorylated with a high
score. This site appears to be highly conserved in vertebrates, from
ﬁsh to mammals, as shown in Fig. 1a. According to ScanProsite,
NetPhos 2.0 and Phosida servers, S29 is phosphorylated by CK2,
despite the presence of a proline at the C-terminal side of the
phosphorylated residue; moreover phosphorylation by GSK3 is also
predicted at S29 by NetPhosK 1.0 server. As shown in Fig. 1a, another
highly conserved consensus site for CK2 is S236, a residue located
upstream of the poly-Q stretch, but outside the Josephin domain,
which is also predicted to be phosphorylated by CK2 by all servers.
S256, another highly conserved phosphorylation site, predicted to be
phosphorylated by GSK3 by NetPhos 2.0 and Phosidia servers, was
already demonstrated to be phosphorylated by this kinase [29]. Other
consensus sites were found in the C-terminal unstructured domain: a
cluster of ﬁve phosphorylation sites predicted to be phosphorylated
either by CK2 or by GSK3 (S268, T271, S272, S273, S277) and the two
serines already demonstrated to be phosphorylated by CK2 by
Mueller and coworkers (S329 and S341 in murine ATXN3,
corresponding to S340 and S352 respectively in human ATXN3)
[25]. However, most of these sites (as well as others such as S321 and
T344) are not predicted to be phosphorylated by all four servers, nor
are they highly conserved, as shown in Fig. 1a.
In order to ascertain whether ATXN3 can be phosphorylated by
CK2, puriﬁed recombinant murine ATXN3Q6, obtained as previously
reported [33], was subjected to in vitro phosphorylation by CK2.
Autoradiography (Fig. 1b) showed that ATXN3 is actually phosphor-
ylated by this kinase, conﬁrming that sites phosphorylatable by CK2
are present in this protein, as previously reported [25,29]. Lower
molecular mass bands are also seen, representing ATXN3 proteolytic
fragments, whose characterization was described in a previous work
[22]. Since none of the existing studies on ATXN3 phosphorylation
had been carried out through mass spectrometry, we decided to
investigate ATXN3 phosphorylation through a proteomic approach.
The study of the role of CK2 phosphorylation at S29 and S236
appeared of particular interest, since these are the most conserved
CK2 phosphorylation sites, the C-terminal domain being more
divergent, and because no previous study had investigated phosphor-
ylation of the N-terminus.
3.2. ATXN3 is phosphorylated in vitro by CK2 and GSK3 on S29
In order to assess which of the predicted CK2 and/or GSK3
phosphorylatable residues are actually phosphorylated, recombinant
ATXN3 was subjected to in vitro phosphorylation by either CK2 or
GSK3, digestion with Glu-C and mass spectrometry analysis. Operat-
ing in the linear mode, upon incubation of wild-type ATXN3 with
either CK2 or GSK3, it was possible to detect peaks corresponding to
monophosphorylated peptides containing S29 (Fig. 2). A list of the
phosphorylated peptides identiﬁed through mass spectrometry is
reported in Fig. 2a. The peak at 3002.13m/zwas also analyzed byMS/
MS TOF-TOF analysis unequivocally conﬁrming the phosphorylation
of ATXN3 on S29 residue (data not shown). Upon phosphatase
treatment the corresponding non-phosphorylated peaks were
detected (data not shown). Fig. 2b reports three of the spectra
relative to the peptides, obtained after phosphorylation with CK2:
peak at 2172.32m/z corresponds to the phosphorylated peptide 27-
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peak at 3002.13m/z corresponds to the phosphorylated peptide 8-32
(8KQEGSLCAQHCLNNLLQGEYFSPVE32, calculated monoisotopic mass
3001.35) and peak at 3516.00m/z corresponds to the phosphorylated
peptide 3-32 (3SIFHEKQEGSLCAQHCLNNLLQGEYFSPVE32, calculated
monoisotopic mass 3516.64). Moreover, mass spectrometric analysis
of the protein ﬁngerprint allowed to detect only peptides containing
unmodiﬁed S236, showing that this residue is not phosphorylated in
such conditions.
Besides the modiﬁcation in the Josephin domain, phosphorylation
at serine residues in the C-terminal portion of the molecule was also
observed: S268, S272, S273, S277, T271, S329 and S341, were all found
to be phosphorylated by CK2; S268, S272, S273 and S277 were also
found to be phosphorylated by GSK3 (data not shown). These ﬁndings
are in accordance with previous data reported by Mueller and
coworkers [25], who described the phosphorylation of human
ATXN3 at S340 and S352, corresponding to murine ATXN3 S329 and
S341 respectively.
Taken together, our results provide evidence that ATXN3 is
phosphorylated in vitro on residue S29 by CK2 and GSK3 and suggest
a direct role of these kinases in in vivo phosphorylation of ATXN3
within the Josephin domain.
3.3. ATXN3 is phosphorylated in transfected COS-7 cells
COS-7 cells overexpressing ATXN3Q6 were collected 24 h after
transfection; the recombinant protein was immunoprecipitated from
crude extracts with anti-ATXN3Q6 polyclonal Z46 antibody and
subsequently loaded onto SDS-PAGE. Bands were detected through
acid silver staining and subjected to in situ digestion with Glu-C
endoproteinase. Mass spectrometry analysis of the protein expressed
in transfected cells unequivocally conﬁrmed that ATXN3Q6 is
phosphorylated at S29, since it was possible to detect phosphopep-
tides containing S29 upon ﬁngerprint mass analysis, as reported in
Table 1 (phosphopeptide 27YFSPVE32, calculated monoisotopic mass
821.34, experimental mass 821.98, and phosphopeptide 27YFSPVELS-
SIAHQLDEEE
44
, calculated monoisotopic mass 2172.97, experimental
mass 2173.02) .
3.4. ATXN3Q6S29A is less efﬁciently translocated to the nucleus than the
wild-type
With the aim of investigating the role of phosphorylation on S29,
this residue was substituted with an alanine, through site-directed
mutagenesis performed with Quik Change Mutagenesis Kit (Strata-
gene La Jolla, CA USA). COS-7 cells were transiently transfected with
plasmid pcDNA3.1/myc-His, expressing either wild-type ATXN3Q6 or
ATXN3Q6S29A carrying an HA epitope at the N-terminus and a c-myc
epitope at the C-terminus. Cells were harvested 24 h after transfection
and cytosolic and nuclear fractions were analysed by Western
blotting, probed with a monoclonal anti-c-myc antibody. Results are
shown in Fig. 3a: the band corresponding to wild-type ATXN3Q6 was
found equally distributed between the cytoplasm and the nucleus. On
the contrary, the band corresponding to S29A mutant was found
much less abundant in the nuclear fraction, being about 25% of the
intensity of the corresponding cytosolic band, as shown by densito-
metric analysis (Fig. 3c); statistical analysis conﬁrmed the existence of
a signiﬁcant difference between nuclear and cytosolic S29A mutant
(pb0.05); no differences were found between nuclear and cytosolic
wild-type ATXN3 (p=0.52). This suggests that S29 phosphorylationFig. 1. In vitro CK2 phosphorylation of ATXN3. (a) T-Coffeemultiple sequence alignment of at
lupus (dog; XP537352), Xenopus laevis (african clawed frog; NP001016389), Bos tauros (d
sapiens (man; BAI46626), Mus musculus (mouse; NP083981), Macaca rhesus (macaque; XP0
are marked. (b) In vitro phosphorylation of puriﬁed recombinant murine ATXN3Q6 (arrow);
Methods) was used as a control.promotes ATXN3 nuclear uptake. Confocal microscopy conﬁrmed
these results: as seen in Fig. 4a wild-type ATXN3Q6 ﬂuorescence, both
red (due to Cy3 conjugated anti-c-myc antibody) and green (due to
Cy2 conjugated anti-HA antibody), was evenly distributed inside the
cells. On the other hand, S29A mutant ﬂuorescence was found to be
much weaker inside the nucleus than in the cytoplasm. The overlay
with the blue ﬂuorescence emission of the nuclear marker conﬁrmed
that wild-type ATXN3 is found also inside the nucleus, while S29A
mutant is found predominantly in the cytosol. Quantitative analysis of
ﬂuorescent emission allowed to assess that S29A mutant ﬂuorescence
in the nuclear region amounted to about 30% of wild-type ATXN3
ﬂuorescence in the same area (Fig. 4b); statistically signiﬁcant
differences were found between wild-type ATXN3 and S29A mutant
(pb0.05);.
In order to conﬁrm the role of S29 phosphorylation on ATXN3
nuclear uptake, this residue was substituted with an aspartic acid,
thus mimicking the presence of the phosphate negative charge. After
ATXN3Q6S29D transient expression in COS-7 cells, cytoplasmic and
nuclear fractions were analysed by Western blotting. Results, shown
in Fig. 3b, showed that S29D behaved exactly like the wild-type, being
equally distributed in the nucleus and the cytoplasm. Consistently, a
uniform ﬂuorescence distribution inside the cells was detected in
confocal microscopy experiments, as shown in Fig. 4a, the overlay
showing colocalization with the nuclear marker. Quantitative ﬂuo-
rescence analysis conﬁrmed that S29D ﬂuorescence in the nuclear
region did not remarkably differ from that of wild-type ATXN3Q6
(Fig. 4b); statistical analysis yielded a p value 0.53, conﬁrming the
absence of any statistically signiﬁcant differences between wild-type
ATXN3 and S29D mutant.
Moreover the same percentage of cells showing the described
subcellular localization was found in all samples considered, as shown
in the last column of Fig. 4a. Cell viability, assayed through MTT test,
showed a 30% reduction for S29A mutant, when compared to both
wild-type protein and S29D mutant; statistical analysis of three
different experiments yielded a p value b0.05 for the comparison
between wild-type ATXN3 and S29A mutant, while a p value of 0.21
was found when comparing wild-type ATXN3 with S29D mutant.
The previously observed [22] 42 kDa fragment, produced by
proteolytic cleavage at S29, was found almost exclusively in the
cytosolic fractions and appeared to be more evident in S29A mutant
than in the wild-type protein and in S29D mutant.
In order to rule out the possibility that the observed phenotype of
S29Amutant might be conﬁned to COS-7 cells, human neuroblastoma
SHSY-5Y cells were also transfected with plasmid pcDNA3.1/myc-His,
expressing either wild-type ATXN3Q6 or ATXN3Q6S29A carrying an
HA epitope at the N-terminus and a c-myc epitope at the C-terminus.
Cytosolic and nuclear fractions, obtained from harvested cells 24 h
after transfection, were analysed by Western blotting, probed with a
monoclonal anti-c-myc antibody. Results, reported in Fig. 3d, show the
absence of S29A in the nuclear fraction, in accordance with what
observed in COS-7 cells.
3.5. CK2 and GSK3 inhibitors demonstrate that both kinases act on S29 in
COS-7 transfected cells
COS-7 cells expressing either ATXN3Q6 or ATXN3Q6S29D were
grown in the presence of CK2 inhibitor TBB (tetrabromobenzotria-
zole) and GSK3 inhibitor SB216763. Inhibitors were added to growth
media either separately or in combination. Western-blots of nuclear
and cytosolic fractions, probedwith anti-c-myc antibody, are shown inaxins-3: Anas platyrhynchos (duck; ABX10879), Danio rerio (zebraﬁsh; AAY28605), Canis
omestic cow; AAI46167), Ornithorhynchus anatinus (platypus; XP001507271), Homo
01116022), Branchiostoma lanceolatum (amphioxus XP002610252); conserved serines
an E. coli crude extract subjected to the same puriﬁcation procedure (see Materials and
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Fig. 2. ATXN3 is phosphorylated on Ser 29 by CK2 and GSK3. (a) 8 μg of ATXN3was phosphorylated in vitro either by CK2 or GSK3. Samples were denatured in 8 M urea and subjected
to reduction and alkylation in solution by iodoacetamide. After dilution and incubation with GluC endoproteinases (1:25 enzyme/protein, w/w) overnight at 37 °C, samples were
analysed byMass analysis (as described in the experimental section). The presence of the phosphate group results in an increase in mass of 80 units or in a decrease of 18 units due to
the loss of the phosphate and a water molecule. (b) Peak at 2172.32 m/z corresponds to the CK2 phosphorylated peptide 27-44 (27YFSPVELSSIAHQLDEEE44, calculated average mass
2172.97), peak at 3002.13m/z corresponds to the CK2 phosphorylated peptide 8-32 (8KQEGSLCAQHCLNNLLQGEYFSPVE32, calculated monoisotopic mass3001.35) and peak at
3516.00 m/z corresponds to the CK2 phosphorylated peptide 3-32 (3SIFHEKQEGSLCAQHCLNNLLQGEYFSPVE32, calculated monoisotopic mass 3516.64) are indicated. Data are
representative of one of three experiments.
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as shown in Fig. 5a, both wild-type ATXN3Q6 and S29D mutant were
found evenly distributed between the cytosol and the nucleus,
suggesting that TBB could not prevent S29 phosphorylation even at
10 μM concentration. The same happened when only GSK3 inhibitor
SB216763 was administered at 10 μM concentration, as shown in
Fig. 5b.
However, when both inhibitors were added to culture medium,
nuclear translocation of wild-type ATXN3Q6 appeared to be reduced,
a behaviour closelymirroring that of S29Amutant (see Fig. 5c); on the
contrary, S29Dmutant appeared to be uniformily distributed between
nucleus and cytosol. Intensities of ATXN3 bands in total extracts were
found to be similar, showing that the mutation did not affect ATXN3
expression levels. These data were conﬁrmed by densitometric
analysis, reported in Fig. 5d, showing that, when both inhibitors
were administered, about 50% of the intensity of the corresponding
cytosolic band of wild-type ATXN3 was found inside the nucleus,
while S29D mutant was equally distributed between the two cellular
compartments; the statistically signiﬁcant difference in nuclear andTable 1
ATXN3 is phosphorylated on Ser 29 in transfected cells. Cell homogenate was separated
by SDS-PAGE and ATXN3Q6 was subjected to reduction, alkylation and in situ digestion
with GluC endoproteinase (1:10 enzyme/protein, w/w). Upon peptide extraction with
40% CH3CN in 0.1% TFA, the peptide mixture was analyzed by mass spectrometry (as
described in Materials and Methods).
ATX3 Peptide Species Predicted mass Identiﬁed mass
Wild
type
27YFSPVE32 P-Ser +80 821.34 821.98
27YFSPVELSSIAHQLDEEE44 P-Ser +80 2172.97 2173.02cytosolic localization of ATXN3 in the presence of the inhibitors was
conﬁrmed by a p value b0.05. Mass spectrometry analysis, performed
on acid silver stained gels after ATXN3Q6 immunoprecipitation from
COS-7 cells cultured in the presence of both TBB and SB216763,
allowed to detect a peptide containing unmodiﬁed S29, (27YFSPVELS-
SIAHQLDEEE44, calculated monoisotopic mass 2092.97, experimental
mass 2092.78), showing that this residue is not phosphorylated when
both CK2 and GSK3 inhibitors are present.
On the whole these data clearly show that CK2 and GSK3 can
concur in the phosphorylation of S29, promoting ATXN3 nuclear
uptake.
4. Discussion
Phosphorylation is well known to play a role in a number of
neurodegenerative diseases, notably in amyloid ﬁbers formation.
Nonaka and coworkers [35] have shown that α-synuclein is
phosphorylated on Ser 129 and that this is crucial in mediating both
protein neurotoxicity and inclusion formation; other authors have
shown that hungtintin is phosphorylated by Cdk5 [36]. Phosphory-
lation has also been reported to protect presenilin-2 from caspase
cleavage [37]. Amongst ataxias, SCA14 is caused by mutations on
residues which are normally phosphorylated: unphosphorylated
proteins do not fold correctly and aggregate [38]; ATXN1, the protein
responsible for Sca1 has been demonstrated to be phosphorylated by
Akt at S776; this phosphorylation creates a binding site for 14-3-3,
increasing ATXN1 stabilization and accumulation and hence leading
to pathogenesis [39,40]. Amongst the kinases involved in neurode-
generative diseases, CK2 and GSK3 are particularly interesting. In
neuronal cells there appears to be a myriad of CK2 substrates that
have clear implications in neural development, neuritogenesis,
Fig. 3.Western-blot analysis of ataxins-3 in COS-7 and SHSY-5Y cells. c-myc tagged full-
length ATXN3Q6 (a, b) and its mutants ATXN3Q6S29A (a) and ATXN3Q6S29D (b) were
expressed in COS-7 cells. Western-blots of cytosolic and nuclear fractions were probed
with a monoclonal anti-c-myc antibody. Cytosolic and nuclear fractions controls were
performed with anti-ﬁbrillarin and anti-PGK antibodies. (c) Densitometric analysis
performed with NIH Image-based software Scion Image (Scion Corporation) on blot
reported in panel a. Bands intensities were normalized on ﬁbrillarin and PGK controls.
Data represent mean ± SD of three independent experiments; signiﬁcant differences
were found between nuclear and cytosolic S29A mutant (* pb0.05); no differences
were found between nuclear and cytosolic wild-type ATXN3 (p=0.52) (d) c-myc
tagged full-length ATXN3Q6 and its mutant ATXN3Q6S29A were expressed in SHSY-5Y
cells. Western-blots of cytosolic and nuclear fractions were probed with a monoclonal
anti-c-myc antibody. Cytosolic and nuclear fractions controls were performed with
anti-ﬁbrillarin and anti-PGK antibodies.
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two isoforms of GSK3 which are found in mammals, GSK3β and
GSK3α [41], GSK3β is particularly abundant in the central nervous
system [30] and has been found to be involved in Alzheimer disease
pathogenesis [42].
Some authors already addressed the issue of ATXN3 phosphory-
lation [15,24,25,29], however, their studies were conducted mainly
through pull-down assays and coimmunoprecipitations.
In this work, we investigated for the ﬁrst time the role of ATXN3
phosphorylation through a proteomic approach. Amongst the differ-
ent putative phosphorylation consensus sites which are found along
ATXN3 sequence, we found that S29, the only phosphorylatable site
within the Josephin domain, can be phosphorylated in vitro by both
CK2 and GSK3. Phosphorylation on S29 was subsequently conﬁrmed
in transfected COS-7 cells overexpressing ATXN3Q6 and was found to
be prevented by the addition of CK2 and GSK3 inhibitors. On the
contrary, S236, another highly conserved phosphorylation site, was
found to be unphosphorylated in mass spectrometry analysis.
Moreover, our data conﬁrmed phosphorylation at C-terminal sites
already described by other authors, such as S256 [29] and S329 and
S341, corresponding to S340 and S352 respectively in human ATXN3[25]. It is worthmentioning that Serine 29 is recognized, by prediction
methods, as part of a consensus sequence for both CK2 and GSK3,
although the presence of a proline nearby is known to prevent
phosphorylation by CK2 in some instances; experimental data
allowed to conﬁrm this prediction.
Our decision to focus on S29 phosphorylation is motivated by the
fact that this residue is highly conserved in vertebrates; moreover, it is
the only putatively phosphorylated site within the Josephin domain
and, according to the NMR determined structure [8] is fully exposed to
the solvent and presumably easily accessible. On the other hand, we
did not focus on consensus sites located in the C-terminal domain,
since they appear to be less conserved and had already been studied
by other authors.
In order to assess whether phosphorylation at S29 could regulate
ATXN3 subcellular localization, we substituted S29 with an alanine,
through site-directed mutagenesis. Results showed that mutation to
alanine strongly reduced nuclear uptake. The fact that, upon
substituting S29 with an aspartic acid, the wild-type phenotype is
restored, shows that the reduction of nuclear uptake is due to the lack
of the negative phosphate charge and not to the aminoacid
substitution. The site of proteolytic cleavage seems to be unaffected
by the lack of phosphorylation; however S29A mutant seems to be
cleaved at S29 to a higher extent than both wild-type and S29D
mutant, suggesting that phosphorylation at this level might hamper
proteolytic cleavage; the double band which is seen in correspon-
dence of S29A 42 kDa fragment is also present in wild-type ATXN3
and is probably an artifact. More work will be necessary to elucidate
the nature and role of the so far unknown protease involved in the
cleavage.
Mass spectrometry analysis also showed beyond any doubt that
ATXN3 is phosphorylated in transfected cells and this strongly
suggests that phosphorylation takes place also in vivo. Moreover,
the fact that CK2 and GSK3 concur in phosphorylating S29 points to
the importance of ATXN3 nuclear translocation. Results obtained with
both inhibitors suggest that no other kinases are involved in this
process.
All our experiments have been performed on murine ATXN3,
carrying only six glutamines and sharing a high similarity with normal
human ATXN3; as stated before [22], the choice of this protein is
justiﬁed by the effort to avoid aggregate formation, which can be
artiﬁcially induced by the unnatural raising in concentration which
takes place inside transfected cells, since the aggregation process
follows a secondorder kinetic [33]. Thepresence of only six glutamines
in murine ATXN3, makes the event rather unlikely. Moreover we
already showed that human ATXN3Q26 behaves exactly like murine
ATXN3Q6when expressed at low levels in transfected cells, as regards
subcellular sorting and proteolytic fragmentation [22].
Our data show a strong reduction in nuclear uptake, which is
nevertheless not completely abolished. The possibility that this event
is controlled by more than one factor is very likely. In a recent paper,
Mueller at al. identiﬁed CK2 phosphorylation on S340 and S352, two
residues which are found downstream of poly-Q, as essential for
nuclear translocation [25]; although, as mentioned above, we did not
focus on phosphorylation at these residues, our data are deﬁnitely not
in contrast with those of Mueller and coworkers. Since S340 and S352
are both found inside UIM3, whose presence in ATXN3 structure
depends on alternative splicing, phosphorylation at S29 may well be
an additional factor promoting nuclear uptake, a process which seems
essential for ATXN3 function. In addition, ATXN3 nuclear uptake does
not seem to be completely suppressed in Mueller and coworkers
experiments [25], neither upon S340/S352 mutagenesis to alanine
nor upon addition of CK2 inhibitors. Last but not least, the fact that
when S29 is substituted with an alanine, a 30% decrease in cell
viability is observed, suggests that nuclear uptake is an important
process for ATXN3 functionality, possibly in relation to its function as
a transcriptional repressor [9,43], and is ﬁnely controlled by more
Fig. 4. Confocal microscopy analysis of ATXN3 subcellular localization. (a) COS-7 cells were transfected with cDNAs coding for ATXN3Q6, or ATXN3Q6S29A and ATXN3Q6S29D
mutants. To investigate sub-cellular localization of ATXN3, cells were ﬁxed in PFA and probed with mouse monoclonal anti-c-myc (red), rabbit monoclonal anti-HA antibodies
(green) and the nuclear marker TO-PRO-3 iodide (blue). Last column reports percentage of observed phenotypes (b) Quantiﬁcation analysis of ﬂuorescence intensities in the nuclear
region of cells overexpressing ATXN3Q6, ATXN3Q6S29A or ATXN3Q6S29D. Data represent mean ± SD of three independent experiments; signiﬁcant differences were found
between wild-type ATXN3 and S29A mutant (* pb0.05); no differences were found between wild-type ATXN3 and S29D mutant (p=0.53).
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[44] showed that CK2 inhibitors are not effective in preventing ATXN3
nuclear localization upon heat-shock; this is well in accordance with
our data showing that only simultaneous inhibition of both CK2 and
GSK3 can prevent ATXN3 nuclear uptake. These authors also showed
that S111, which is found inside a Polo-like kinase phosphorylation
site, is involved in ATXN3 nuclear uptake following heat-shock; we
propose that this residue be involved in nuclear uptake promoted by
heat-shock or oxidative stress, while phosphorylation at S29, S340
and S352 could regulate normal ATXN3 trafﬁcking between the
nucleus and the cytoplasm. This is strongly supported by the fact that,
in Reina and coworkers experiments, S111 mutation to alanine
decreases ATXN3 nuclear localization but does not suppress it.
Whether a putative NLS, which is found in ATXN3 primary
sequence, is essential for ATXN3 nuclear translocation is still
controversial: in a previous work [22] we showed that a truncated
mutant lacking this sequence was only slightly less efﬁciently
translocated into the nucleus; Mueller and coworkers, as well as
Reina and coauthors, recently conﬁrmed that NLS mutation has no
effect on ATXN3 subcellular distribution. On the other hand otherauthors [45] showed, through a yeast nuclear import assay, that
ATXN3 NLS is functional and essential for nuclear uptake.
Nuclear translocation of ATXN3 is also of the utmost importance
for SCA3 pathogenesis, since amyloid aggregates are found primarily
inside the nucleus. Although a growing amount of data suggest that
mitochondrial damage is also involved in SCA3 pathogenesis [46–48],
the presence of nuclear aggregates is a hallmark of many neurode-
generative diseases and impairment of nuclear functions is very likely
to induce cell death. Our data strongly suggest that inhibiting S29
phosphorylation, strongly reduces ATXN3 nuclear uptake. This in turn
leads to the key question of how S29 phosphorylation is involved in
SCA3 pathogenesis. In a previous work [22] we suggested that a toxic
poly-Q containing fragment is produced from incomplete proteolysis
of pathological human ATXN3Q72, which can trigger aggregation of
pathological undegraded ATXN3, upon reaching a critical concentra-
tion insidemitochondria and the nucleus. Recently, Hubener et al. [49]
showed that in transgenic mice nuclear aggregation of pathological
ATXN3 occurs even when an expanded ATXN3 carrying a NES is
coexpressed and demonstrated that double transgenic mice, expres-
sing both normal and pathological ATXN3 show the same disease
Fig. 5.Western-blot analysis of COS-7 cells treated with kinase inhibitors. (a) c-myc tagged full-length ATXN3Q6 and its mutant ATXN3Q6S29Dwere expressed in COS-7 cells treated
with TBB 5 or 10 μM (CK2 inhibitor) or with DMSO, as a control. (b) c-myc tagged full-length ATXN3Q6 and its mutant ATXN3Q6S29D were expressed in COS-7 cells treated with SB
216763 10 μM(GSK3 inhibitor) or with DMSO, as a control. (c) c-myc tagged full-length ATXN3Q6 and itsmutant ATXN3Q6S29Dwere expressed in COS-7 cells treated with both TBB
10 μM (CK2 inhibitor) and SB 216763 10 μM (GSK3 inhibitor) or with DMSO, as a control. (d) Densitometric analysis performed with NIH Image-based software Scion Image (Scion
Corporation) on blot reported in panel c. Bands intensities were normalized on ﬁbrillarin and PGK controls. Data represent mean± SD of three independent experiments; signiﬁcant
differences were found between nuclear and cytosolic wild-type ATXN3 in the presence of CK2 and GSK3 inhibitors (* pb0.05); no differences were found between nuclear and
cytosolic S29D mutant in the presence of CK2 and GSK3 inhibitors (pN0.5) (a, b, c,) Western-blots of total extracts, cytosolic fraction and nuclear fraction were probed with a
monoclonal anti-c-myc antibody. Cytosolic and nuclear fractions controls were performed with anti-ﬁbrillarin and anti-PGK antibodies.
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proteins; this is consistent with the idea that aggregation is a
concentration process and could also be explained by the already
proposed hypothesis of expanded polyQ stretching giving rise to
membrane channels. Moreover another recent work [50] showed that
the C-terminus of Hsp70-interacting protein (CHIP) suppresses
ATXN3Q70 neurotoxicity in transgenic mice, preventing the forma-
tion of toxic microaggregates. Ubiquitinylation by either E4B or CHIP
is essential to target misfolded ATXN3 to the proteasome [10,24]. Data
of different authors [24,25] have shown that pathological ATXN3 is
also a substrate of CK2, suggesting that phosphorylation may target
pathological ATXN3 to the nucleus, where it will readily form
aggregates, escaping ubiquitinylation and targeting to proteasomal
degradation. Further work will be undertaken in order to understand
the role of CK2 and GSK3 in SCA3 pathogenesis.
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